CD56、CD117在多发性骨髓瘤中的表达及其与临床病理特征的相关性
|
摘要
目的探讨CD56、CD117在多发性骨髓瘤(MM)中的表达及其与临床病理特征的相关性。方法选取MM患者80例作为MM组,同期选择体检的健康者80例作为对照组,采用流式细胞仪检测2组入选者血液中的CD56、CD117表达,分析患者的临床病理资料并进行相关性分析。结果观察组的CD56、CD117表达阳性率分别为40. 0%和30. 0%,对照组分别为8. 8%和10. 0%,观察组显著高于对照组(P <0. 05)。CD56、CD117的表达与多发性骨髓瘤的临床分期、Ig H重排、M蛋白类型、轻链类型显著相关(P <0. 05),与患者年龄、性别无关(P> 0. 05)。Spearman等级相关分析显示CD56表达阳性率与CD117表达阳性率呈显著正相关性(P <0. 05)。结论 CD56、CD117在MM患者中都呈现高表达状态,与患者的临床分期、免疫特征等显著相关,可作为MM免疫球蛋白分型的指标。
Objective To investigate the expression of CD56 and CD117 in multiple myeloma( MM) and its correlation with the clinicopathological features. Methods 80 patients with MM were selected as the MM group,and the other 80 cases of healthy subjects were selected as control group. Used the flow cytometry to detect the expression of CD56 and CD117 in the two groups,and were to analysis the clinical opathological data of the patients and the correlation analysis. Results The positive rates of CD56 and CD117 expression in the observation group were 40. 0% and 30. 0%,respectively,while those in the control group were 8. 8% and 10. 0%,respectively,which the observation group were significantly higher than in the control group( P < 0. 05).The expression of CD56 and CD117 was significantly associated with clinical stage,Ig H rearrangement,M protein type,and light chain type of MM( P < 0. 05),but not with patients' age or sex( P > 0. 05). Spearman rank correlation analysis showed that the positive rate of CD56 expression was positively correlated with the positive rate of CD117 expression( P < 0. 05). Conclusion The CD56 and CD117 are highly expressed in MM patients,which are significantly correlated with clinical stages and immune characteristics,and can be used as indicators of MM immunoglobulin typing.
Objective To investigate the expression of CD56 and CD117 in multiple myeloma( MM) and its correlation with the clinicopathological features. Methods 80 patients with MM were selected as the MM group,and the other 80 cases of healthy subjects were selected as control group. Used the flow cytometry to detect the expression of CD56 and CD117 in the two groups,and were to analysis the clinical opathological data of the patients and the correlation analysis. Results The positive rates of CD56 and CD117 expression in the observation group were 40. 0% and 30. 0%,respectively,while those in the control group were 8. 8% and 10. 0%,respectively,which the observation group were significantly higher than in the control group( P < 0. 05).The expression of CD56 and CD117 was significantly associated with clinical stage,Ig H rearrangement,M protein type,and light chain type of MM( P < 0. 05),but not with patients' age or sex( P > 0. 05). Spearman rank correlation analysis showed that the positive rate of CD56 expression was positively correlated with the positive rate of CD117 expression( P < 0. 05). Conclusion The CD56 and CD117 are highly expressed in MM patients,which are significantly correlated with clinical stages and immune characteristics,and can be used as indicators of MM immunoglobulin typing.
引文
[1]Ceran F,Falay M,Da?da?S,et al.The assessment of CD56and CD117 expressions at the time of the diagnosis in multiple myeloma patients[J].Turk J Haematol,2017,34(3):226-232.
[2]Marks E,Shi Y,Wang Y.CD117(KIT)is a useful marker in the diagnosis of plasmablastic plasma cell myeloma[J].Histopathology,2017,71(1):81-88.
[3]韩文敏,张修文,贾祝霞,等.多发性骨髓瘤患者NK细胞杀伤功能异常的研究[J].中华血液学杂志,2015,36(11):922-925.
[4]Bagwell JM,Herd HR,Breshears MA,et al.Concurrent multiple myeloma and mast cell neoplasia in a 13-year-old castrated male Maine Coon cat[J].Vet Clin Pathol,2017,46(1):151-157.
[5]李二敏,欧阳建,周敏,等.表达CD19+CD56-的多发性骨髓瘤浆细胞免疫表型的鉴别[J].现代生物医学进展,2014,14(24):4641-4643.
[6]Jian CX,Fan QS,Hu YH,et al.IL-7 suppresses osteogenic differentiation of periodontal ligament stem cells through inactivation of mitogen-activated protein kinase pathway[J].Organogenesis,2016,12(4):183-193.
[7]徐源.DC-CIK治疗难治性多发性骨髓瘤的临床研究[J].实用癌症杂志,2015,30(3):454-456.
[8]Dong F,Hao S,Ma S,et al.A novel lymphoid progenitor cell population(LSK(low))is restricted by p18(INK4c)[J].Exp Hematol,2016,44(9):874-885.
[9]Limvorapitak W,Srisum-Ang T,Chimres C,et al.Accuracy of bone marrow flow cytometry analysis in patients with plasma cell neoplasm in thailand:A single institutional study[J].Clin Lymphoma Myeloma Leuk,2016,16(3):e27-e37.
[10]Pan Y,Wang H,Tao Q,et al.Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma[J].Leuk Res,2016,1(40):77-82.
[11]张宏,范银银,戴晓莉,等.3种设门方法在多发性骨髓瘤免疫表型分析中的应用比较[J].临床检验杂志,2015,33(3):181-184.
[12]Pojero F,Casuccio A,Di Bassiano F,et al.Correlation between CD117+myeloma plasma cells and hematopoietic progenitor cells in different categories of patients[J].Immun Ageing,2015,4(12):5.
[13]Flores MJ,de Tute R,Paiva B,et al.Immunophenotype of normal vs.myeloma plasma cells:Toward antibody panel specifications for MRD detection in multiple myeloma[J].Cytometry B Clin Cytom,2016,90(1):61-72.
[14]Kamande JW,Lindell MAM,Witek MA,et al.Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics[J].Integr Biol(Camb),2018,10(2):82-91.
[15]Iyoda T,Yamasaki S,Hidaka M,et al.Amelioration of NKcell function driven by Vα24(+)invariant NKT cell activation in multiple myeloma[J].Clin Immunol,2018,2(187):76-84.
[16]高露,刘清,师岩,等.应用CD138免疫磁珠分选结合荧光原位杂交技术检测多发性骨髓瘤细胞遗传学异常[J].中国实验血液学杂志,2017,25(3):807-812.
[17]Krejcik J,Frerichs KA,Nijhof IS,et al.Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab[J].Clin Cancer Res,2017,23(24):7498-7511.
[18]Wagner JA,Rosario M,Romee R,et al.CD56bright NK cells exhibit potent antitumor responses following IL-15 priming[J].J Clin Invest,2017,127(11):4042-4058.
[19]Nakano H,Kato K,Nomura S,et al.A case of a solitary plasmacytoma extending into the extradural space[J].No Shinkei Geka,2017,45(9):811-817.
[20]Sharma A,Binazir T,Sintow A,et al.An extremely rare manifestation of multiple myeloma:an immunoglobulin D secreting testicular plasmacytoma[J].Cureus,2017,9(6):e1400.
[21]Dosani T,Mailankody S,Korde N,et al.Host-related immunodeficiency in the development of multiple myeloma[J].Leuk Lymphoma,2018,59(5):1127-1132.
[22]王亚哲,路瑾,郝乐,等.4色与8色荧光抗体组合检测多发性骨髓瘤患者微小残留病的比较分析[J].中华血液学杂志,2017,38(4):272-278.
[23]Iriyama N,Miura K,Hatta Y,et al.Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib[J].Oncol Lett,2017,13(5):3803-3808.
[24]Folch J,Petrov D,Ettcheto M,et al.Masitinib for the treatment of mild to moderate Alzheimer's disease[J].Expert Rev Neurother,2015,15(6):587-596.
[2]Marks E,Shi Y,Wang Y.CD117(KIT)is a useful marker in the diagnosis of plasmablastic plasma cell myeloma[J].Histopathology,2017,71(1):81-88.
[3]韩文敏,张修文,贾祝霞,等.多发性骨髓瘤患者NK细胞杀伤功能异常的研究[J].中华血液学杂志,2015,36(11):922-925.
[4]Bagwell JM,Herd HR,Breshears MA,et al.Concurrent multiple myeloma and mast cell neoplasia in a 13-year-old castrated male Maine Coon cat[J].Vet Clin Pathol,2017,46(1):151-157.
[5]李二敏,欧阳建,周敏,等.表达CD19+CD56-的多发性骨髓瘤浆细胞免疫表型的鉴别[J].现代生物医学进展,2014,14(24):4641-4643.
[6]Jian CX,Fan QS,Hu YH,et al.IL-7 suppresses osteogenic differentiation of periodontal ligament stem cells through inactivation of mitogen-activated protein kinase pathway[J].Organogenesis,2016,12(4):183-193.
[7]徐源.DC-CIK治疗难治性多发性骨髓瘤的临床研究[J].实用癌症杂志,2015,30(3):454-456.
[8]Dong F,Hao S,Ma S,et al.A novel lymphoid progenitor cell population(LSK(low))is restricted by p18(INK4c)[J].Exp Hematol,2016,44(9):874-885.
[9]Limvorapitak W,Srisum-Ang T,Chimres C,et al.Accuracy of bone marrow flow cytometry analysis in patients with plasma cell neoplasm in thailand:A single institutional study[J].Clin Lymphoma Myeloma Leuk,2016,16(3):e27-e37.
[10]Pan Y,Wang H,Tao Q,et al.Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma[J].Leuk Res,2016,1(40):77-82.
[11]张宏,范银银,戴晓莉,等.3种设门方法在多发性骨髓瘤免疫表型分析中的应用比较[J].临床检验杂志,2015,33(3):181-184.
[12]Pojero F,Casuccio A,Di Bassiano F,et al.Correlation between CD117+myeloma plasma cells and hematopoietic progenitor cells in different categories of patients[J].Immun Ageing,2015,4(12):5.
[13]Flores MJ,de Tute R,Paiva B,et al.Immunophenotype of normal vs.myeloma plasma cells:Toward antibody panel specifications for MRD detection in multiple myeloma[J].Cytometry B Clin Cytom,2016,90(1):61-72.
[14]Kamande JW,Lindell MAM,Witek MA,et al.Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics[J].Integr Biol(Camb),2018,10(2):82-91.
[15]Iyoda T,Yamasaki S,Hidaka M,et al.Amelioration of NKcell function driven by Vα24(+)invariant NKT cell activation in multiple myeloma[J].Clin Immunol,2018,2(187):76-84.
[16]高露,刘清,师岩,等.应用CD138免疫磁珠分选结合荧光原位杂交技术检测多发性骨髓瘤细胞遗传学异常[J].中国实验血液学杂志,2017,25(3):807-812.
[17]Krejcik J,Frerichs KA,Nijhof IS,et al.Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab[J].Clin Cancer Res,2017,23(24):7498-7511.
[18]Wagner JA,Rosario M,Romee R,et al.CD56bright NK cells exhibit potent antitumor responses following IL-15 priming[J].J Clin Invest,2017,127(11):4042-4058.
[19]Nakano H,Kato K,Nomura S,et al.A case of a solitary plasmacytoma extending into the extradural space[J].No Shinkei Geka,2017,45(9):811-817.
[20]Sharma A,Binazir T,Sintow A,et al.An extremely rare manifestation of multiple myeloma:an immunoglobulin D secreting testicular plasmacytoma[J].Cureus,2017,9(6):e1400.
[21]Dosani T,Mailankody S,Korde N,et al.Host-related immunodeficiency in the development of multiple myeloma[J].Leuk Lymphoma,2018,59(5):1127-1132.
[22]王亚哲,路瑾,郝乐,等.4色与8色荧光抗体组合检测多发性骨髓瘤患者微小残留病的比较分析[J].中华血液学杂志,2017,38(4):272-278.
[23]Iriyama N,Miura K,Hatta Y,et al.Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib[J].Oncol Lett,2017,13(5):3803-3808.
[24]Folch J,Petrov D,Ettcheto M,et al.Masitinib for the treatment of mild to moderate Alzheimer's disease[J].Expert Rev Neurother,2015,15(6):587-596.